Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15–25% of all metastatic melanoma patients. It currently does no...

Descripción completa

Detalles Bibliográficos
Autores principales: Boespflug, Amélie, Caramel, Julie, Dalle, Stephane, Thomas, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502949/
https://www.ncbi.nlm.nih.gov/pubmed/28717400
http://dx.doi.org/10.1177/1758834017708160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502949/
https://www.ncbi.nlm.nih.gov/pubmed/28717400
http://dx.doi.org/10.1177/1758834017708160

Ejemplares similares